NCT00197041View on ClinicalTrials.gov

A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

PHASE2CompletedINTERVENTIONAL
Enrollment

2,022

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Malaria
Interventions
BIOLOGICAL

RTS,S/AS02A

Trial Locations (1)

Unknown

GSK Investigational Site, Maputo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00197041 - A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique. | Biotech Hunter | Biotech Hunter